VERSIONS OF DISINTEGRIN AND THEIR PHARMACEUTICAL APPLICATION Russian patent published in 2019 - IPC C07K14/46 C12N15/12 A61K38/16 A61P27/02 A61P35/00 

FIELD: biotechnology.

SUBSTANCE: invention relates to the field of biotechnology, specifically to the preparation of disintegrin variants, and can be used in medicine for the treatment of the integrin disease, selected from age-related macular degeneration, diabetic retinopathy, corneal neovascularisation diseases induced by neovascularisation of retinopathy ischemia, high myopia, premature retinopathy, metastatic melanoma, metastatic prostate cancer, metastatic breast cancer, colorectal cancer, liver cancer, ovarian cancer, cervical cancer, pancreatic cancer, non-small cell lung cancer and glioblastoma multiforme. A variant of disintegrin containing a mutant RGD loop and a mutant linker and / or a mutant end is obtained from rhodosthosin.

EFFECT: invention enables to obtain a version of disintegrin with reduced binding activity with integrin aIIbb3 and high binding activity with at least avb3 and a5b1 integrins as compared to disintegrin, not having a mutant RGD loop and a mutant linker and / or a mutant C-terminal.

10 cl, 12 dwg, 14 tbl, 15 ex